Terminated PHASE2 INTERVENTIONAL 2-arm NCT01551368

Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients (nimodipine)

Using Nimodipine, a Calcium Channel Blocker, to Prevent the LH Surge and Ovulation in Women Undergoing Assisted Reproduction

Sponsor: Mount Sinai Hospital, Canada

Conditions Infertility

Interventions Nimodipine Placebo

Updated 6 times since 2017 Last updated: Mar 6, 2019 Started: Dec 31, 2012 Primary completion: Apr 30, 2014 Completion: Jul 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

small number of patients got recruited

Other terminated trials from Mount Sinai Hospital, Canada

See all terminations from Mount Sinai Hospital, Canada

Other Infertility trials with similar outcome

Browse all Infertility trials

Listed as NCT01551368, this PHASE2 trial focuses on Infertility and remains terminated or withdrawn. Sponsored by Mount Sinai Hospital, Canada, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Apr 2019 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Apr 2019 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mount Sinai Hospital, Canada

Data source: Mount Sinai Hospital, Canada

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada